Diligence memo · auto-generated · as of July 3, 2026
Aprecia Pharmaceuticals Co
Aprecia Pharmaceuticals Co looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Aprecia Pharmaceuticals Co operates in Pharmaceuticals, based in LANGHORNE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aprecia Pharmaceuticals Co has raised $175M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $79M on 2016-01-13.
Most recent recorded round closed around 2016-01-13.
Valuation (modeled)modeled
Provath models Aprecia Pharmaceuticals Co at approximately $2.8B (range $257M–$7.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.19× the median modeled value of Series C Pharmaceuticals companies in 2016–2018 (32 peers) — value vs value, same stage and era. Within the normal band (119% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 10.5 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 96% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Amplyx Pharmaceuticals, Inc., Ligand Pharmaceuticals Inc, Homology Medicines, Inc., KSQ Therapeutics, Inc., TP Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.